LatestIP And Trademarks 30 October 2026
India Rejects TB Alliance BPaL Patent, Opens Generic Market
India’s Patent Office has denied the TB Alliance’s application for a patent on its BPaL regimen, a treatment for drug‑resistant tuberculosis. The decision removes a major barrier, allowing Indian manufacturers to produce generic versions and potentially expand access to affordable therapy for patients nationwide.
India’s Patent Office has rejected the TB Alliance’s patent request for the BPaL regimen, a key therapy against drug‑resistant TB.
- Impact: Clears the way for Indian pharmaceutical companies to develop and sell generic versions of BPaL.
- Benefit: Could lower treatment costs and increase availability for patients across the country.
For full details, see the original report on eHealth Eletsonline.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.